Press Releases

Press Releases

or

January 7, 2021
CAMBRIDGE, Mass. & BEIJING --(BUSINESS WIRE)--Jan. 7, 2021-- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the Company will participate in the J.P.
December 6, 2020
Zanubrutinib was shown to be highly active in patients with relapsed/refractory marginal zone lymphoma in initial results from the Phase 2 MAGNOLIA trial Zanubrutinib demonstrated an overall response rate of nearly 95 percent and a sustained progression-free survival in treatment-naïve chronic
December 1, 2020
CAMBRIDGE, Mass. & BEIJING --(BUSINESS WIRE)--Dec. 1, 2020-- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced the pricing of an underwritten public offering of 1,511,546
December 1, 2020
CAMBRIDGE, Mass. & BEIJING --(BUSINESS WIRE)--Dec. 1, 2020-- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced the commencement of an underwritten public offering of 1,511,546